Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Asia Deal Watch: Juniper Licenses Asia-Pacific-Plus Rights To Kolon’s Osteoarthritis Cell Therapy

Executive Summary

Plus deals involving Shionogi/NEC, Ji Xing/LENZ, Kyowa Kirin/Ardelyx, CR Pharma/Everest Medicine and Dr Reddy’s/Novartis.

You may also be interested in...



Arteryex Acquisition To Enhance Eisai's Digital Strategy

Eisai is acquiring Japanese software company Arteryex as part of a digital shift strategy, with the two companies to work together to develop and provide services around personal data, including health records.

Dr Reddy’s Continues To Capitalize On German Cannabinoids With MediCane Launch

Dr Reddy's has announced that it will market MediCane’s medical cannabis portfolio across Germany, as part of a collaboration between the two companies which began last year.

Next Big Step: SK Bioscience Gears Up For Endemic COVID, Next Pandemic

With its COVID-19 vaccine development project nearing the finish line, SK Bioscience unveils an ambitious growth strategy which includes mergers and acquisitions and diversification into the cell and gene therapy sector.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC146243

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel